Skip to content

The mechanism of action of QiShen YiQi DiWan in improving myocardial fibrosis and strain force in patients with heart failure with preserved ejection fraction was studied by quantitative analysis based on Notch signaling pathway and ultrasonic spot tracking technology

The mechanism of action of QiShen YiQi DiWan in improving myocardial fibrosis and strain force in patients with heart failure with preserved ejection fraction was studied by quantitative analysis based on Notch signaling pathway and ultrasonic spot tracking technology

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600117679
Enrollment
Unknown
Registered
2026-01-27
Start date
2025-09-08
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart failure with preserved ejection fraction

Interventions

Treatment group:Add QiShen YiQi Dropping Pills
control group:conventional therapy

Sponsors

Zhejiang Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patients with HFpEF who met the diagnostic criteria 2. Age above 18 years old, both sexes 3. TCM syndrome differentiation is qi deficiency and blood stasis syndrome 4. They voluntarily received the drug treatment and signed an informed consent form

Exclusion criteria

Exclusion criteria: 1. Previous LVEF <40% 2. Patients with New York Heart Association (NYHA) class ? 3. Patients with severe cardiopulmonary dysfunction, severe arrhythmia, serious primary diseases of the liver, kidney and hematopoietic system, or serious diseases affecting their survival (such as tumors, etc.) and mental patients; 4. Patients with poor image quality 5. Patients known to be allergic to the investigational drug (including its components) 6. Pregnant or women planning to become pregnant, and lactating women 7. Patients who have participated in other clinical studies within the past month

Design outcomes

Primary

MeasureTime frame
TCM syndrome score;6-minute walk test;LVGLS;

Secondary

MeasureTime frame
Notch signaling pathway-related proteins ;

Countries

China

Contacts

Public ContactXu Xiaohong

Zhejiang Hospital

syxuxiaohong@163.com+86 571 8159 5087

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 7, 2026